Hengrui Pharmaceutical announced that it intends to sign the "Shanghai Shengdi Biomedical Private Investment Fund Partnership (Limited Partnership) Partnership Agreement" (hereinafter referred to as the "Partnership Agreement") with its holding subsidiaries, Shengdi Investment and Hengrui Group, to jointly initiate the establishment of a partnership. enterprise.
The total subscribed capital contribution of the partnership is 2.01 billion yuan, of which Shengdi Investment will contribute 10 million yuan as a general partner (GP), with a shareholding ratio of 0.5%, and the company and Hengrui Group will contribute as a limited partner (LP) respectively. 1,000,000,000 yuan, and the shareholding ratio is 49.75%.The source of funds of the company is its own funds.
Hengrui Medicine stated in the announcement that theinvestment fund will, in accordance with the provisions of laws and regulations and the agreement of the partnership agreement, uphold the standards of innovation, value and growth, carry out equity investment business around the medical and health industry, invest in high-quality enterprises in the medical and health field, and focus on the field of biomedicine. innovative research and development, to build a biopharmaceutical industry ecosystem and a leading domestic biopharmaceutical innovation investment platform.The investment fund is conducive to meeting the needs of the company's business and strategic development, in line with the company's existing and future business development direction, and is conducive to the company's long-term development.
This investment will not affect the normal development of the company's main business.There are still uncertainties in the follow-up investment operation of the investment fund, and there may be investment risks such as not being able to achieve investment returns and failing to recover investment costs.The company will actively pay attention to the follow-up fundraising and investment work of investment funds, strengthen the focus on investment projects, and strictly control investment risks.
(Editor: Duan Jingyuan)
